Xeltis
2006
FOUNDED
PRIVATE
STATUS
31-40
EMPLOYEES
Series D
LATEST DEAL TYPE
$12.2M
LATEST DEAL AMOUNT
6
INVESTORS
Description
Developer of medical devices designed for Endogenous Tissue Restoration (ETR). The company's medical device platform comprises bioabsorbable cardiovascular valves and vessels that use endogenous tissue restoration technology, enabling the patient's own body to naturally form a new heart valve through a therapeutic approach.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Primary Office
- Seefeldstrasse 35
- 8008 Zurich
- Switzerland
+41 044 000 00 00
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Xeltis’s full profile, request a free trial.
Xeltis Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series D) | 05-Sep-2019 | $12.2M | 000.00 | Completed | Clinical Trials - General | |
| 3. Later Stage VC (Series C) | 15-Nov-2017 | 000.00 | 000.00 | Completed | Clinical Trials - General | |
| 2. Later Stage VC (Series B) | 24-Sep-2015 | $33.7M | $33.7M | Completed | Clinical Trials - General | |
| 1. Early Stage VC | Completed | Startup |
Xeltis Competitors (17)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| QT Vascular | Corporation | Singapore, Singapore | 0000 | 000000000 | 0000 | |
| 000000000 | Corporate Backed or Acquired | Framingham, MA | 000 | 00000 | 000000&0 | 00000 |
| 0000000 0000000000 | Venture Capital-Backed | Kirkland, WA | 00 | 00000 | 00000000000 | 00000 |
| 000 | Formerly PE-Backed | Leesburg, VA | 000 | 00000 | 000000&0 | 00000 |
| 000000 0000000000 | Failed Transaction (M&A) | Marlborough, MA | 00000 | 000000&0 |
Xeltis Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Ysios Capital | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Kurma Partners | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Life Sciences Partners | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| StartAngels Network | Angel Group | Minority | 000 0000 | 000000 0 | ||
| VI Partners | Venture Capital | Minority | 000 0000 | 000000 0 |
Xeltis Executive Team (30)
7 Former Executives
You’re viewing 5 of 30 executives. Get the full list »Xeltis Board Members (10)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Christian Wenger Ph.D | Self | Board Member | 000 0000 | |
| Clemens Van Blitterswijk Ph.D | Life Sciences Partners | Board Member | 000 0000 | |
| Karen Wagner | Ysios Capital | Board Member | 000 0000 | |
| Martin De Groot | Xeltis | Chief Financial Officer & Board Member | 000 0000 | |
| Michael Colson | Self | Chairman of the Scientific Advisory Board | 000 0000 |
4 Former Board Members
You’re viewing 5 of 10 board members. Get the full list »